Lucitanib may benefit selected patients with metastatic breast cancer
The VEGFR1-3, FGFR1-3 and PDGFRα/β inhibitor lucitanib shows modest antitumour activity and significant hypertension-related toxicity in patients with HR-positive, HER2-negative metastatic breast cancer, according to data from the phase II FINESSE study. Interestingly, the drug appears to confer greater benefits to patients with high FGFR1 expression.
